Prostate Cancer News Archive: 31-May-2006

• Prostate Cancer Detection And Screening Session I - AUA 2006 (Medical News Today)
  UroToday.com - A Podium Session on prostate cancer Detection and Screening took place on Sunday May 21, 2006 at the annual AUA meeting in Atlanta. Some highlights from the 12 papers presented are as follows. Dr. Ian Thompson, San Antonio, TX reported on ability for PSA to detect CaP in finasteride treated patients. [click link for full article]



• Ambrilia Reports Issuance of U.S. Patent on PCK3145, its Lead Drug Candidate for Advanced Metastatic Prostate Cancer (Market Wire via Yahoo! Finance)
  U.S. Patent No. 7053058 covers the Signal Transduction Inhibitor PCK3145 and related sequences



• Prostate Cancer Basic Research Session I - AUA 2006 (Medical News Today)
  UroToday.com - A Discussed Poster Session on Prostate Cancer Basic Research took place on Sunday May 21, 2006 at the annual AUA meeting in Atlanta. Many interesting posters on basic and potential translation science were presented. A few of these are described herein. Dr. [click link for full article]



• Prostate Cancer Detection And Screening Session II - AUA 2006 (Medical News Today)
  UroToday.com - A Moderated Poster Session on Prostate Cancer Detection and Screening took place on Sunday May 21, 2006 at the annual AUA meeting in Atlanta. Some highlights from the posters presented are as follows. Dr. Anthony D'Amico, Boston MA reported that the pre-biopsy PSA velocity (PSAV) predicts only for high-grade CaP in those patients with a positive prostate biopsy. [click link for



• Gen-Probe, DiagnoCure Provide Updates on PCA3 Prostate Cancer Collaboration and Development Programs (PR Newswire via Yahoo! Finance)
  Gen-Probe Incorporated and DiagnoCure Inc. provided three updates today on the companies' collaboration and development programs around the innovative, highly specific PCA3 prostate cancer marker.



• Johns Hopkins Researchers Present Advances In Prostate Cancer Program At The Annual Meeting Of The American Urological (Medical News Today)
  Ciphergen Biosystems,Inc. (Nasdaq: CIPH) announced the discovery of two biomarkers that may aidin the management of prostate cancer, including for the detection, staging,and prediction of recurrence. [click link for full article]

Back to Prostate Cancer News Archives